← Back to Clinical Trials
Recruiting Phase 3 NCT06814626

NCT06814626 Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06814626
Status Recruiting
Phase Phase 3
Sponsor The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Condition Liver Cirrhosis
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2022-10-13
Primary Completion 2025-12

Trial Parameters

Condition Liver Cirrhosis
Sponsor The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 72
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2022-10-13
Completion 2025-12
Interventions
12-week nutritional intervention with Friliver dispensing12-week nutritional intervention with personalized diet12-week nutritional intervention with diet diary to report foods eaten.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The hypothesis is that in patients with cirrhosis and refractory ascites candidate to TIPS, and sarcopenia (identified by a PMA ≤16 cm² at the level of L3), who are at high-risk of 6-month mortality after TIPS placement, a post-TIPS 12 weeks nutritional intervention is associated with improved post-TIPS prognosis. The primary objective is to evaluate the effect of a post-TIPS 12 weeks nutritional intervention on liver transplant-free six-month survival in sarcopenic candidates to TIPS for refractory ascites in cirrhosis.

Eligibility Criteria

Inclusion Criteria: * men and women with an age ≥ 18 and ≤ 80 years * clinical, radiological or histological diagnosis of liver cirrhosis * diagnosis of RA * confirmation of sarcopenia defined in CT scan as the sum of the psoas muscle areas measured at the level of the 3rd lumbar vertebra (PMA) ≤16 cm2 * informed consent signed Exclusion Criteria: * severe hepatic insufficiency (bilirubin\> 5 mg/dl, MELD score\> 18, Child-Pugh score\> 9) * Congestive heart failure class ≥2 according to New York Heart Association criteria (NYHA) * Active coronary heart disease (myocardial infarction within 6 months of the study) * Severe pulmonary hypertension suspected on echocardiogram (systolic pulmonary arterial pressure \[PAPs\]\> 35 mmHg) and confirmed with right cardiac catheterization (PAPs\> 45mmHg) * Chronic renal failure (creatinine\> 3 mg/dl) * Performance status ≥2 according to the Eastern Cooperative Oncology Group scale (ECOG) * History of grade III-IV hepatic encephalopathy or West Haven

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology